Clearing Away the Clutter: Implementing Value-Based Contracting in Pharma.

DIAGNOSIS; DRUG efficacy; BIOMARKERS; FEE for service (Medical fees); OCCUPATIONAL roles; CELLULAR therapy; ARTIFICIAL intelligence; VALUE-based healthcare; HEALTH insurance reimbursement; TREATMENT effectiveness; PRIMARY health care; INTERPROFESSIONAL relations; HEALTH insurance; DRUGS; GENE therapy; PHARMACEUTICAL industry; PHYSICIANS; MEDICARE; ECONOMICS

The article highlights Value-Based Contracts (VBCs) for expensive treatments like cell and gene therapies, analyzing insights from industry leaders like EVERSANA CEO Jim Lang and Molecular You CEO Jim Kean. It also discusses the challenges, trends, and potential solutions related to VBC implementation, including issues with payment structures, patient outcomes, regulatory hurdles, and leveraging new technologies like biomarkers and AI for better healthcare strategies and VBC success.